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Background. To compare the early outcome of combined SMILE and collagen crosslinking (SMILE Xtra) with SMILE. Method.
Prospective, comparative interventional study of 21 eyes receiving SMILE Xtra using a low energy protocol and 32 control eyes
receiving SMILE only. The outcomes were compared at 1, 3, and 6 months postoperatively. Results. Both groups had myopia with
spherical equivalent refraction (SEQ) > 4.00D. The SMILE Xtra group had thinner preoperative central corneal thickness and
residual stromal bed thickness (𝑝 < 0.021). At 6 months, no eyes lost more than 1 line in corrected distance visual acuity.The safety
index was 0.96±0.06 and 1.00±0.00 in SMILE Xtra and control, respectively (𝑝 < 0.001). 89% and 94% of eyes were within ±0.50D
of target refraction, respectively, with the mean error in SEQ correction being −0.17±0.26D for SMILE Xtra and +0.03±0.25D for
control (𝑝 = 0.021). The efficacy index was 0.88 ± 0.13 and 0.97 ± 0.06, respectively (𝑝 = 0.005). Conclusion. SMILE Xtra had good
overall safety profile and predictability at 6months. However, when compared with control, the safety index and efficacy index were
statistically significantly lower in the early postoperative period.
1. Introduction
Small-incision lenticule extraction (SMILE) is a recently
developed corneal refractive procedure that has been shown
to be safe and effective in correcting myopia [1–5]. The
procedure involves cutting a small lenticule in the corneal
stroma with a femtosecond laser, which is subsequently
removed through a 2 to 3mm small incision. Compared with
laser in situ keratomileusis (LASIK), where a flap is created
then lifted, SMILE is a flapless procedure and avoids the flap-
related complications seen in LASIK surgery. It was shown
in a randomized study that SMILE had comparable outcome
with femtosecond-assisted LASIK [6–8].
In LASIK, a rare but devastating complication is iatro-
genic corneal ectasia, where there is progressive corneal
steepening and thinning resulting in increasing myopia and
astigmatism and decrease in visual acuity. Although post-
LASIK ectasia cannowbe effectively treatedwith crosslinking
[9], advanced cases may still require keratoplasty. The main
risk factors for developing post-LASIK ectasia include preex-
isting forme fruste keratoconus and a thin residual stromal
bed (RSB) thickness [10, 11]. Factors that contribute to a thin
RSB thickness include thin preoperation corneal thickness,
correction of high myopia, and a thick flap. Therefore,
careful preoperative patient selection is most important in
the prevention of post-LASIK ectasia. As post-LASIK ectasia
is thought to be related to the weakened biomechanical
properties in post-LASIK eyes, prophylactic strengthening of
the cornea with simultaneous cross-linking (LASIK Xtra) has
been increasingly used in recent years [12–15], particularly in
patients with young age, high myopia or high hyperopia, thin
corneal thickness, and thin RSB thickness. The development
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of SMILE aimed for a biomechanically stronger cornea by
preserving the integrity of the anterior cornea due to its
flapless nature. Although large case series have demonstrated
an excellent safety profile of SMILE [2], corneal ectasia after
SMILE in eyes with preexisting forme fruste keratoconus has
been reported [16, 17]. Combining collagen cross-linkingwith
SMILE (SMILE Xtra) will have the potential advantage of
restrengthening the cornea, which theoretically can reduce
the risk of ectasia development and also regression ofmyopia.
The purpose of this study is to compare the 6-month clinical
outcome of a series of SMILE Xtra cases using a low energy
protocol with SMILE alone.
2. Materials and Methods
A total of 21 consecutive eyes from 12 patients who have
undergone SMILE Xtra between January and March 2015 at
a private ophthalmic center in Hong Kong were recruited
prospectively. A random sample of 32 eyes from 18 patients
receiving SMILE alone (without CXL) during the same
period were also recruited to serve as control. Inclusion
criteria of the study included moderate to high myopia with
baseline spherical equivalent refraction (SEQ) higher than
4 diopters, and all eyes had a plano target refraction. All
patients had signed an informed consent before the refractive
procedure. The study was approved by the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong KongWest Cluster (Reference number: UW
15-226) and adhered to the tenets of the Declaration of
Helsinki.
All patients underwent complete ophthalmic evaluation
before the procedure and had no ocular comorbidities other
than myopia and myopic astigmatism. All patients had
preoperative CDVA of 20/20 or better. The ectasia risk factor
score was also calculated based on the system proposed by
Randleman, which took topographic pattern, age, CCT, RSB
thickness, and SEQ into consideration [11]. The additional
option of SMILE Xtra was offered to patients with a higher
ectasia risk score. Although this scoring system was devel-
oped for LASIK, it was applied here given that a modified
version does not yet exist for SMILE. Exclusion criteria for
SMILE procedure included unstable refraction, topographic
evidence of forme fruste keratoconus, significant ocular
diseases, previous corneal surgery, autoimmune diseases or
medications that affect wound healing, and pregnant or
lactating patients.
2.1. Operative Procedures. Thesame surgeon (GC) performed
all the surgery under topical anesthesia. SMILE was per-
formed using the 500-kHz VisuMax femtosecond laser (Carl
ZeissMeditec, Jena,Germany) using an established technique
[4]. The following parameters were used: cap thickness, 110–
120𝜇m; cap diameter, 7.0–7.5mm; lenticule diameter, 6.0–
6.5mm with a transition zone of 0.1mm; cut energy, 1.4 𝜇J;
spot and tracking distance, 2.0–3.0 𝜇m. The back of the
intrastromal lenticule was created from periphery to center
of the cornea. The anterior lamellar cut was subsequently
created from center to periphery of the cornea, which
extended toward the surface to create a 2mm incision located
at 12 o’clock position (for left eye) or 10 o’clock position (for
right eye), from which the stromal lenticule was extracted. A
thin blunt spatula was used to separate the lenticule, which
was then grasped with a pair of forceps and removed. The
corneal interface was flushed with balanced salt solution.
The same normogram was used for both groups. For cases
with combined cross-linking, after lenticule removal, 0.22%
riboflavin with saline (VibeX Xtra, Avedro) was instilled
through the small incision into the interface and allowed for
a soak time for 45 seconds. An additional 2mm incision at
the opposite site was created to allow for complete irrigation
of the riboflavin solution. This was followed by ultraviolet
A irradiation at 18mW/cm2 for 45 seconds (total energy:
0.8 J/cm2) using the CXL-365 variosystem (Schwind, Ger-
many).
Postoperative medications included topical tobramycin
0.3% and dexamethasone 0.1% ophthalmic suspension four
times a day for 1 week. Preservative-free artificial teardrops
were used for 3 months postoperatively. All patients were
examined preoperatively and at postoperative day 1, week
1, month 1, month 3, and month 6. Assessments included
monocular uncorrected distance visual acuity (UDVA) and
CDVA, manifest refraction, and slit-lamp and fundus exam-
ination. Corneal thickness was measured with a scanning-
slit topography (Orbscan; Bausch & Lomb, Rochester, NY).
Efficacy index was calculated as the ratio of postoperative
UDVA over preoperative CDVA and safety index was deter-
mined as the ratio of postoperative CDVA over preoperative
CDVA. Outcome measures included postoperative UDVA,
CDVA, corneal thickness, efficacy index, safety index, and
the predictability of the correction. Any complications arising
from the procedure were reported.
2.2. Statistical Analysis. Statistical analysis was performed
using SPSS version 21 (IBM, Chicago).
The patient demographics will be reported with descrip-
tive statistics.
The parameters between SMILE Xtra and control group
were compared with Mann-Whitney 𝑈 test for age, Fisher’s
exact test for gender, and linear mixed model analysis for
other parameters to account for the effect of both eyes from
the same patients. 𝑝 < 0.05 was considered statistically
significant.
3. Results
A total of 21 SMILE Xtra eyes (12 patients) and 32 SMILE eyes
(18 patients) were included for analysis. All eyes aimed for a
plano correction. The average age was 28.1 ± 6.1 in SMILE
Xtra and 27.5 ± 5.2 in control (𝑝 = 0.966). The baseline
parameters of both groupswere shown inTable 1. Both groups
had comparable age, gender distribution, spherical equivalent
refraction (SEQ), and mean keratometry. The SMILE Xtra
group had significantly lower central corneal thickness. The
RSB thicknesswas 288±33 𝜇min SMILEXtra and 311±30 𝜇m
in control (𝑝 < 0.008). 14 SMILE Xtra eyes (66.7%) had
an ectasia risk factor score of 4 or higher (high risk) and 4
eyes (19.0%) had a score of 3 (moderate risk). In the control
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Figure 1: Visual outcomes for small-incision lenticule extraction (SMILE) (left) and combined SMILE with cross-linking (SMILE Xtra)
(right) at the end of 6 months, showing the (a) change in preoperative and postoperative corrected distance visual acuity (CDVA) and (b) the
cumulative percentage of eyes attaining specified cumulative levels of postoperative uncorrected distance visual acuity (UDVA).
Table 1: Baseline parameters of combined small-incision lenticular
extraction (SMILE) and collagen cross-linking (SMILE Xtra) versus
SMILE.
SMILE Xtra SMILE(control) 𝑝 value
Age 28.1 ± 6.1 27.5 ± 5.2 0.966a
Sex (male : female) 4 : 8 9 : 9 0.465b
Sphere (diopter) −6.59 ± 1.55 −6.05 ± 1.09 0.124c
Cylinder (diopter) −0.96 ± 0.72 −1.02 ± 0.47 0.567c
Spherical equivalent
refraction (diopter) −7.08 ± 1.67 −6.56 ± 1.05 0.167
c
Mean keratometry
(diopter) 43.71 ± 1.56 43.37 ± 1.28 0.396
c
Central corneal
thickness (𝜇m) 518 ± 39 545 ± 22 0.007
c∗
aMann-Whitney U test.
bFisher’s exact test, by subject.
cLinear mixed model, by eye.
∗
𝑝 < 0.05.
group, 5 eyes (15.6%) were of high risk and 5 eyes (15.6%) had
moderate risk.
3.1. Visual Acuity, Safety, and Efficacy. For CDVA, no eyes
in either group had lost 2 or more lines at all visits till
postoperative month 6 (Figure 1). Six eyes (33%) lost 1 line of
CDVA in the SMILE Xtra group while no eye had lost CDVA
in the control group. At 6 months, only 67% eyes in SMILE
Xtra group achieved UDVA 20/25 or better, while all except
2 eyes (94%) in the control group had UDVA 20/25 or better
(Figure 1).
The safety index and efficacy index of both groups at
months 1, 3, and 6 were shown in Table 2. Both indices were
statistically significantly lower in the SMILE Xtra group than
control at all visits. No intraoperative or postoperative com-
plications occurred in either group. Postoperatively, therewas
no clinically detectable corneal haze in all cases.
3.2. Refraction, Predictability, and Stability. Themean spher-
ical equivalence reduced from −7.08D to −0.17D at 6 months
postoperatively in SMILE Xtra and from −6.56D to +0.03D
in control. At 6 months, 94% and 97% of eyes in the SMILE
group were maintained within ±0.50D in the SEQ and
astigmatism correction, respectively. In SMILE Xtra group,
89% and 94% of eyes were within ±0.50D in SEQ and
astigmatism correction, respectively (Figure 2). The mean
errors in the correction in the SEQ at 6 months were
−0.17 ± 0.26D for SMILE Xtra and +0.03 ± 0.25D for control
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Figure 2: Refractive outcomes for small-incision lenticule extraction (SMILE) and combined SMILE with cross-linking (SMILE Xtra) at
the end of 6 months postoperatively: (a) attempted versus achieved manifest spherical equivalent refraction (SEQ) correction in diopters for
SMILE (left) and SMILE Xtra (right); (b) percentages of eyes within different diopter ranges of the intended correction in SEQ after SMILE
and SMILE Xtra; (c) percentage of eyes attaining specified levels of astigmatism before (white) and after (grey) SMILE and SMILE Xtra.
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Figure 3: Time course of manifest spherical equivalent refraction (SEQ) after small-incision lenticule extraction (SMILE) and combined
SMILE with cross-linking (SMILE Xtra).
Table 2: The safety indices (postoperative CDVA/preoperative
CDVA) and efficacy indices (postoperative UDVA/preoperative
CDVA) of both groups at postoperative months 1, 3, and 6.
Month 1 Month 3 Month 6
Safety index
SMILE Xtra 0.95 ± 0.08 0.95 ± 0.06 0.96 ± 0.06
SMILE 1.03 ± 0.09 1.00 ± 0.04 1.00 ± 0.00
𝑝 value∗ 0.004 0.005 <0.001
Efficacy index
SMILE Xtra 0.89 ± 0.11 0.89 ± 0.10 0.88 ± 0.13
SMILE 0.96 ± 0.08 0.98 ± 0.07 0.97 ± 0.06
𝑝 value∗ 0.013 0.001 0.005
∗Linear mixed model analysis.
(𝑝 = 0.021). Figure 3 shows that a slightmyopic shifting trend
is demonstrated in the SMILE Xtra group while the SMILE
group demonstrated stability over 6 months.
3.3. Corneal Thickness. The baseline CCT and RSB thickness
were thinner in the SMILE Xtra group. However, at 6 months
postoperatively, the CCT in SMILE Xtra group was 420 ±
39 𝜇m,which was similar to control (408±32 𝜇m, 𝑝 = 0.507).
4. Discussion
Studies have demonstrated that SMILE is a safe procedure
and has comparable outcome with femtosecond-LASIK [1, 3,
4, 6–8]. There is still debate whether SMILE is biomechan-
ically stronger when compared with LASIK. Sinha Roy et
al. proposed that SMILE might present less biomechanical
risk to the residual bed of susceptible corneas than LASIK
based on finite-element analysis [18]. Two clinical studies
found less reduction in biomechanical properties measured
with ORA after SMILE compared with LASIK [19, 20],
especially in eyes with myopia more than 6 diopters. On
the other hand, Pedersen et al. and Sefat et al. reported
similar reduction in biomechanical propertiesmeasuredwith
Corvis ST and ORA after LASIK or SMILE [21, 22]. From
current evidence, it was still inconclusive whether the cornea
after SMILE is biomechanically stronger than after LASIK.
Theoretically, the cornea after SMILE is stronger than LASIK
due to less disruption of the collagen fibers in the anterior
stroma. However, the biomechanical strength is inevitably
reduced after any corneal laser refractive procedures.The use
of simultaneous cross-linking to restrengthen or compensate
for the corneal biomechanical strength has therefore been
proposed, especially together with LASIK (LASIK Xtra).
In viewof theweakening effect on the stroma after LASIK,
the use of LASIK Xtra had gained popularity in the past
few years and has reported good refractive and topographic
stability comparable with LASIK alone [12–15]. However,
there was still a lack of standardized procedure protocol and
patient selection criteria. Various irradiation protocols have
been reported, and the UVA energy dose ranged from 1.35–
5.4 J/cm2.The rationale for adding simultaneous crosslinking
for the patients in our SMILE Xtra group was similar to
LASIK Xtra. Our SMILE Xtra eyes had a significantly thinner
CCT and RSB thickness than the control, with an increased
risk of ectasia. We applied the riboflavin directly to the
stromal pocket after lenticule extraction, followed by UVA
irradiation with a total energy of 0.8 J/cm2 (18mW/cm2 for
45 seconds). This method of performing cross-linking was
in fact very similar to the concept of intrastromal cross-
linking in treatment of keratoconus, where a corneal stromal
tunnel was created using femtosecond laser (either alone or in
conjunction with intrastromal corneal ring segment implan-
tation) [23, 24]. Intrastromal crosslinkingwith a pocket depth
of 70 to 100 𝜇mand total energy ranging from 3.6 to 6.3 J/cm2
have been shown to be safe and effective in stabilizing
keratoconus [23, 24]. However, results from animal studies
on the biomechanical effect were inconclusive [25, 26].There
was no standardized protocol in the irradiation intensities
and durations in the literature. Similarly, the optimal dose of
delivering the UVA in SMILE Xtra is yet to be determined
[27, 28]. Graue-Hernandez et al. performed SMILE Xtra on
eyes with forme fruste keratoconus where they employed
the standard Dresden protocol with 5.4 J/cm2 total energy,
and good refractive outcomes were reported at two years
[27]. Another recent study by Ganesh and Brar reported
good safety outcome at 1 year after performing SMILE Xtra
on at-risk (but not forme fruste keratoconus) eyes [28],
where a protocol of 45mW/cm2 for 75 seconds (total energy:
3.4 J/cm2) was used.
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The UVA energy dose in our SMILE Xtra series
(0.8 J/cm2) was lower compared with those used in other
LASIK Xtra or SMILE Xtra protocols (1.35–5.4 J/cm2). Previ-
ously, we have employed a stronger protocol with 60 seconds’
soak time and 60 seconds’ irradiation time.We found around
10% of cases still had clinical observable haze at 6 months
(unpublished data). As a prophylactic treatment, a good
balance between corneal restrengthening and visual outcome
is preferred. Therefore, in this study, we employed a lower-
energy protocol to minimize the postoperative haze. Unfor-
tunately, due to limitation of resources, our study did not
performbiomechanical studies to study the effect of the cross-
linking. For the clinical effect, one would expect long-term
studies (in terms of years) are needed to prove the benefit
of SMILE, which has been shown to be a relatively stable
procedure. A recently published 5-year SMILEoutcome study
showed stable refraction in SMILE with 0.48D regression
over 5 years [29]. The reported regression over 5 years in
LASIK ranged from 0.6 to 0.96D [1, 30]. Therefore, the main
purpose of this current study is to report the short-term
visual and refractive outcome of SMILE Xtra with a low
energy protocol. The other reason that we used a low energy
protocol was to avoid a continued corneal flattening effect,
which was reported in the treatment of keratoconus using
the usual energy dose (5.4 J/cm2) [31].This continued corneal
flattening effect is desirable in keratoconus treatment, but
not in refractive surgery in healthy eyes. Since the energy
dose we employed was much lower, the flattening effect was
expected to be much less. We put emphasis on striking a
balance between prophylaxis and good visual outcome.
Our SMILE Xtra results reported a high level of refractive
predictability. At 6months, 89% of our SMILE Xtra eyes were
within ±0.50D from target and 100% were within ±1.00D,
and this was also comparable with refractive predictability
reported in the literature [4, 5]. However, both our SMILE
Xtra group and their results had a small undercorrection at
6 months. This could be explained by a lack of normogram
adjustment for SMILE Xtra. This slight undercorrection also
explained the small difference in the efficacy index between
our SMILE Xtra and control, where at 6 months only 67%
SMILE Xtra eyes had UDVA reaching 20/20, compared with
94% in control.
In our SMILE cases, the safety index at 3 and 6 months
postoperatively was 1.00. This was comparable to the largest
reported series by Ivarsen et al., where their safety index at
3 months was 1.05 [2]. In our SMILE Xtra cases, the safety
index was slightly lower at 0.95 and 0.96 at 3 and 6 months,
respectively.Nevertheless, no eyes in our series lostmore than
1 line ofCDVA, and thiswas the same as the SMILEXtra series
reported by Ganesh and Brar [28], where no eyes lost more
than 1 line of CDVA either.This difference could be explained
by subclinical corneal stromal haze induced by cross-linking
in our SMILEXtra eyes.Moreover, since the stromal interface
was irrigated with riboflavin solution and cross-linked, the
wound healing response at the stromal interface could be
altered compared with SMILE alone.
A limitation of the current work was unable to per-
form direct biomechanical measurements due to limited
resources. Nevertheless, it had been shown that direct in
vivomeasurement of the corneal biomechanical property had
low specificity and sensitivity [32]. The slight myopic shift
demonstrated in our SMILE Xtra group could as well be
due to an inadequate CXL effect to strengthen the cornea
of our SMILE Xtra cases (where the preoperative corneas
are thinner). The strengthening effects of SMILE Xtra have
been supported by an ex vivo study on human cornea by
Kanellopoulos et al., which showed that combining cross-
linking with refractive lenticule (5mm diameter and 80 𝜇m
thickness at 140 𝜇mdepth) extraction resulted in significantly
increased biomechanical properties compared with control
non-cross-linked eyes [32]. We did not routinely check the
endothelial cell count either, as it has already been shown
that there was no significant change in the endothelial cell
count before and after SMILE [33] or in SMILE Xtra [28].
Other limitations of this study included small sample size
and a relatively short follow-up. Our center only had routine
follow-up until 6 months postoperatively since it is a private
practice setting. Therefore, we aim to report the early safety
and predictability of this procedure only. Given the regression
after SMILE was only 0.48D over 5 years [29], we believe
only long-term data is required to study the beneficial effect
of SMILE Xtra compared with SMILE alone. This emerging
technique has the potential to restore the biomechanical
strength of the cornea after refractive procedures. We have
proposed a low energy protocol to strike a balance between
prophylaxis and visual outcome. However, more long-term
research data are required to guide the optimal protocol of
simultaneous cross-linking.
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